Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

ClinicalTrials.gov ID: NCT06899126

Public ClinicalTrials.gov record NCT06899126. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

Study identification

NCT ID
NCT06899126
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Daiichi Sankyo
Industry
Enrollment
686 participants

Conditions and interventions

Interventions

  • Trastuzumab Deruxtecan Drug
  • pembrolizumab Drug
  • Pemetrexed Drug
  • Platinum Chemotherapy Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 23, 2025
Primary completion
Apr 23, 2030
Completion
Nov 23, 2032
Last update posted
Jul 1, 2026

2025 – 2032

United States locations

U.S. sites
20
U.S. states
12
U.S. cities
19
Facility City State ZIP Site status
Alaska Oncology & Hematology, LLC Anchorage Alaska 99508 Recruiting
Orange Coast Memorial Medical Center Fountain Valley Fountain Valley California 97208 Recruiting
California Research Institute Los Angeles California 90027 Recruiting
Los Angeles Cancer Network (LACN) Los Angeles California 91204 Recruiting
Providence Medical Foundation Santa Rosa California 95403 Recruiting
Bay Pines VA Healthcare System Bay Pines Florida 33744 Recruiting
Lynn Cancer Institute Center Boca Raton Florida 33486 Recruiting
Holy Cross Hospital Fort Lauderdale Florida 33308 Recruiting
Mid-Florida Hematology & Oncology Centers, P.A. Orange City Florida 33763 Recruiting
BRCR Global Plantation Plantation Florida 33321 Recruiting
Hope and Healing Cancer Services Hinsdale Illinois 60521 Recruiting
Dana-Farber Cancer Institute Boston Massachusetts 02216 Recruiting
Logan Health Research Kalispell Montana 59901 Recruiting
Clinical Research Alliance Westbury New York 11590 Active, not recruiting
FirstHealth Cancer Center Pinehurst North Carolina 28374 Recruiting
Gabrail Cancer Center Canton Ohio 44718 Recruiting
St. Charles Health System Bend Oregon 97701 Recruiting
University of Texas M. D. Anderson Cancer Center Houston Texas 77030 Recruiting
Lumi Research Kingwood Texas 77339 Recruiting
Summit Cancer Treatment Center Spokane Washington 99208 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 140 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06899126, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 1, 2026 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06899126 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →